CLINICAL LASERTHERMIA SYSTEMS

Clinical Laserthermia Systems (CLS) develops and markets the TRANBERG®|Thermal Therapy System, as well as disposable materials and methods, for heat-induced immunotherapy enabling safe and gentle treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for CLS’ own immunostimulating therapy, imILT®. The company is headquartered in Lund, Sweden, with subsidiaries in Berlin, Germany and in Boston, USA. CLS is listed on Nasdaq First North under the stock symbol CLS B.